DiscoveRx and BioFocus Announce Co-marketing Agreement for GPCR Screening
News Oct 09, 2009
BioFocus® and DiscoveRx corp. announced has that they have signed a co-marketing agreement that allows BioFocus to perform screening on behalf of BioFocus’ customers using DiscoveRx PathHunter™ ß-Arrestin GPCR screening assay, HitHunter™ cAMP assays and associated cell lines.
DiscoveRx has a portfolio of non-force coupled GPCR cell lines utilizing its award winning PathHunter™ ß-Arrestin GPCR platform as well as HitHunter™ cAMP detection. These validated cell lines and associated detection platform have been used in numerous drug discovery campaigns for de-orphanization and identifying novel hits.
“The addition of the DiscoveRx GPCR product portfolio to BioFocus will enhance our assay development and screening platform” said Chris Newton, SVP BioFocus. “Our customers will gain advantage of our expertise coupled with the unique and complete GPCR portfolio offered by DiscoveRx”.
”We are pleased that BioFocus and DiscoveRx have forged a partnership as both parties bring novel and unique capabilities and technologies to meet challenges of drug discovery customers” said Pyare Khanna, CEO of DiscoveRx.
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018